跨性别男性子宫内膜异位症患病率的系统综述
该系统综述检索五个数据库2000年1月至2024年2月的文献,纳入13项研究共1597名跨性别男性,汇总子宫内膜异位症患病率为8.9%(126/1423,95%CI:7.4-10.5%),非月经性盆腔痛报告率为53.9%(580/1076,95%CI:50.9-56.9%)。作者指出数据量少和基于手术表现的研究存在偏倚是局限。
要点
- 跨性别男性子宫内膜异位症汇总患病率为8.9%(126/1423,95%CI:7.4-10.5%)。
- 手术诊断亚组患病率为9.2%(50/543,95%CI:7.1-11.9%),其中40%为1期病变(10/25)。
- 非月经性盆腔痛报告率为53.9%(580/1076,95%CI:50.9-56.9%)。
核心结论
- 该系统综述确定跨性别男性人群中子宫内膜异位症患病率为8.9%(126/1423,95%CI:7.4-10.5%)。
- 作者指出数据量少以及基于手术表现的研究存在潜在偏倚是局限。
- 跨性别男性参与者中盆腔痛报告率高,53.9%报告非月经性盆腔痛(580/1076,95%CI:50.9-56.9%)。
研究设计与样本
- 系统综述,检索MEDLINE(OVID)、EMBASE、Cochrane Library、Web of Science(通过Clarivate)和CINAHL Complete(EBSCO)五个数据库,检索时间范围为2000年1月至2024年2月。
- 纳入标准:研究人群为跨性别、易性症或跨性别男性个体;参与者报告子宫内膜异位症、盆腔痛或痛经中至少一种情况;2000年1月1日至2024年2月1日期间以英文发表于同行评审期刊。
- 共筛选90篇文章,纳入13项研究,包含1597名跨性别男性,平均年龄26.7岁(SD:8.1岁)。
- 使用Covidence系统综述软件2024进行数据提取,使用非随机干预研究偏倚风险工具(ROBINS-I)评估偏倚风险。
主要发现
- 子宫内膜异位症汇总患病率为8.9%(126/1423,95%CI:7.4-10.5%)。
- 7项研究专门报告手术诊断的子宫内膜异位症,该亚组患病率为9.2%(50/543,95%CI:7.1-11.9%)。
- 诊断为子宫内膜异位症者中40%为1期病变(10/25)。
- 非月经性盆腔痛报告率为53.9%(580/1076,95%CI:50.9-56.9%),性交困难为39.0%(221/566,95%CI:35.0-43.2%),痛经为27.7%(106/383,95%CI:23.0-32.0%),异常子宫出血为22.1%(181/818,95%CI:19.0-25.0%)。
- 睾酮使用报告率为65.5%(926/1413,95%CI:63.0-68.0%),平均治疗时长2.4年(SD:1.1年)。
关键数值与推荐
- 子宫内膜异位症汇总患病率8.9%(126/1423,95%CI:7.4-10.5%)。
- 手术诊断亚组患病率9.2%(50/543,95%CI:7.1-11.9%)。
- 1期病变占诊断病例的40%(10/25)。
- 非月经性盆腔痛53.9%(580/1076,95%CI:50.9-56.9%),性交困难39.0%(221/566,95%CI:35.0-43.2%),痛经27.7%(106/383,95%CI:23.0-32.0%),异常子宫出血22.1%(181/818,95%CI:19.0-25.0%)。
- 睾酮使用65.5%(926/1413,95%CI:63.0-68.0%),平均治疗时长2.4年(SD:1.1年)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 数据量少。
- 基于手术表现的研究存在潜在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This systematic review aims to synthesize available evidence on the prevalence of endometriosis in the trans male population. DATA SOURCES: A systematic review search was conducted using five databases: MEDLINE (OVID), EMBASE, Cochrane Library, Web of Science (via Clarivate), and CINAHL Complete (EBSCO), which were searched between January 2000 and February 2024. METHODS OF STUDY SELECTION: Studies were eligible for inclusion if they: (1) included transgender, transsexual, or trans male individuals as the study population; (2) included participants reporting one or more of the following conditions: endometriosis, pelvic pain, or dysmenorrhoea; (3) were published in a peer-reviewed journal in English between 1 January 2000 and 1 February 2024. Abstracts were screened and reviewed for relevance. Reviewers independently assessed the full-text articles. Data was extracted from the full-text articles using the data extraction tool, Covidence systematic review software 2024. The risk of bias was evaluated using the Risk Of Bias In Non-randomized Studies of Interventions tool. TABULATION, INTEGRATION, AND RESULTS: Of 90 articles screened, 13 were included comprising 1,597 trans men, with a mean age of 26.7 years (SD: 8.1 years). The pooled prevalence of endometriosis was 8.9% (126/1423, 95%CI: 7.4-10.5%). Seven of the studies reported specifically on surgical diagnosis of endometriosis, with a similar prevalence noted in this subset of participants of 9.2%; (50/543; 95% CI: 7.1-11.9%). Those diagnosed with endometriosis were found to have stage 1 disease in 40% of cases (10/25). Non-menstrual pelvic pain was reported by 580 of 1076 participants (53.9%; 95%CI: 50.9-56.9%), dyspareunia by 221 of 566 (39.0%; 95%CI: 35.0-43.2%), dysmenorrhea by 106 of 383 (27.7%; 95%CI: 23.0-32.0%), and abnormal uterine bleeding by 181 of 818 (22.1%; 95%CI: 19.0-25.0%). Testosterone use was reported in 926 of 1,413 participants (65.5%; 95%CI: 63.0-68.0%), with a mean treatment duration of 2.4 years (SD: 1.1 years). CONCLUSION: This systematic review determined a prevalence of endometriosis of 8.9% in the trans male population. Notably, both the low volume of data and potential for bias in studies based on surgical presentation are limitations. There is a high rate of pelvic pain reported among trans male participants, with 53.9% reporting non-menstrual pelvic pain.
引用
- Gerstl B, Sheppard M, Guo B, et al. A Systematic Review of the Prevalence of Endometriosis in Trans Men. J Minim Invasive Gynecol. 2025. PMID: 41061894. doi:10.1016/j.jmig.2025.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。